Breaking News

Drugmakers are turning telehealth into a marketing gold mine; complexity of Covid vaccine program causes concern

  

 

Daily Recap

STAT+: 'This is pharma's dream': How drugmakers are turning telehealth into a marketing gold mine

By Katie Palmer

Hyacinth Empinado/STAT

Online prescribing platforms have seen demand among pharmaceutical companies skyrocket over the past two years.

Read More

Complexity of Covid vaccine program leads to concerns about potential for error

By Helen Branswell

Adobe

Even before the addition of new booster shots, more than 5,300 errors in vaccine dose delivery in kids were reported, according to CDC data.

Read More

Daily multivitamins improved the brain function of seniors in a trial — but plenty of questions remain

By Jonathan Wosen

Adobe

Among the unanswered questions is whether the benefits seen in the trial will translate into real-world benefits.

Read More

STAT+: Medical pioneers team up to launch new cell therapy biotech

By Allison DeAngelis

Courtesy Del Mar Photographics

Capstan Therapeutics plans to create cell therapies, particularly ones that transform a person’s T cells into cancer-fighting warriors.

Read More

Opinion: Listen: A pediatric doctor on the life-or-death decisions some prospective parents must make

By Patrick Skerrett

A pediatric ENT discusses one procedure where parents must choose, at multiple stages, whether to prioritize a mother's life or a child's. 

Read More

U.S. to spend more than $2 billion to launch Biden's biomanufacturing initiative

By Allison DeAngelis

KENZO TRIBOUILLARD/AFP via Getty Images

The initiative will fund efforts to build or expand manufacturing sites and ready raw materials needed to respond to a new pandemic.

Read More

Opinion: A challenge trial can streamline testing of hepatitis C vaccines

By Andrea L. Cox

Wikimedia Commons

Ethically conducting a clinical trial for a new hepatitis C vaccine is a long, slow road. A challenge trial could speed things along.

Read More

Wednesday, September 14, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments